Literature DB >> 23799753

Partial anomalous pulmonary venous connections: surgical management.

José Fragata1, Manuel Magalhães, Luis Baquero, Conceição Trigo, Fátima Pinto, Isabel Fragata.   

Abstract

Partial anomalous pulmonary venous connections (PAPVCs) are a heterogeneous group of congenital heart lesions in which at least one pulmonary vein will drain into the systemic venous system. The consequences are a variable left-to-right hemodynamic shunt and more rarely pulmonary artery hypertension. Often, PAPVC occurs in association with other congenital cardiac malformations. Surgical correction is most often advisable and is generally straightforward and simple to achieve. Historically, some repairs have included incision across the junction of the superior vena cava with the right atrium, which can lead to late arrhythmias. The Warden technique avoids incision across the atriocaval junction. Neonates and infants with Scimitar syndrome represent the most challenging subset of patients with PAPVC.

Entities:  

Keywords:  anomalous; pulmonary; return; veins

Mesh:

Year:  2013        PMID: 23799753     DOI: 10.1177/2150135112460250

Source DB:  PubMed          Journal:  World J Pediatr Congenit Heart Surg        ISSN: 2150-1351


  3 in total

1.  Cardiovascular MR angiography in partial anomalous pulmonary venous connection.

Authors:  Jan Menke
Journal:  BMJ Case Rep       Date:  2015-03-12

2.  Misdiagnosis of anomalous pulmonary venous connections in a patient with lung cancer and a review of the literature.

Authors:  Nicola Tamburini; Irene Marchi; Matteo Bassi; Gabriele Anania; Francesco Quarantotto; Giorgio Cavallesco; Pio Maniscalco
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

3.  Echocardiographic diagnosis of anomalous pulmonary venous connections: Experience of 84 cases from 1 medical center.

Authors:  Ziming Zhang; Li Zhang; Feng Xie; Bing Wang; Zhengxing Sun; Shuangshuang Kong; Xinfang Wang; Nianguo Dong; Guohua Wang; Qing Lv; Yuman Li; Ling Li; Mingxing Xie
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.